 Andre, it's so nice to see you. I'm not certain I read the news release properly, but your company has made a deal with an $87 billion size market cab company. Is that correct? That's really correct, yes. Nice to see you again, too, Tracy. And of course, it's my understanding that with this company, according to one of the research reports I read, this company has, what is it, 15,000 plus stores across Canada have exclusive distribution rights for your FLARE AI technology? Right, so what we did with the SELOR, SELOR's market is essentially just the optometry market. They sell lenses, eyewear to them, and they're a 24.4 billion euro company on an annual basis. So they actually sell about 100 million euro per day. And their market, like I said, is really optometry. What we did with NULOOK is actually build a specific version of our software to analyze retina images for optometrists. And our latest release is going to go into production next week. And based on that, that's one of the reasons that SELOR has decided to go with diagnosed. They also analyzed every single company in our space worldwide, in China, in US, and all over the place. And we came up the winner as our first AI company to help SELOR Luxorica. So specifically in terms of stores, in Canada, we're going to go after 3,600 new stores. NULOOK has 400, so that's not part of the 3,600. And also we have a commitment from SELOR to start working with their existing banners. So the banners that belong to SELOR 100%, such as Lenscrafter, Pearl Vision, and they have many, many around the world. So we're going to be attacking this in parallel with SELOR Canada. Okay. And allow me to correct myself. They've got 18,000 retail store base and 4,000 Canadian distribution clients. If I read this correctly, they're anticipating revenue for Diagnose, which basically exceeds your current market valuation for next year. Should I read that correct? Yes. The correctness, the approach that we have with SELOR is a very strategic one. The main objective is to actually increase the number of people going into their stores. And one way to do this is to make the optometrists more productive. So meaning they can see more patients. So with our technology, we're going to increase the number of new walk-ins or new tests per patient by two patients per day per store. It doesn't look like much, but when you have 18,000 store, it gets to very, very, very large numbers. So that's what we're going to do with them. I would like to go back for just a second, though. I mean, SELOR could select anybody with the size of their company. They picked Diagnose for Canada. Clearly, the FLAIR AI technology is something that they find competitive. Can you talk to me a little bit more about how you were selected in this process? And I'm certain that investors out there are going, how long does it take for respectfully a small cap company to go in and make a deal with a multi-billion dollar, nearly a hundred billion dollar market cap company? Well, it's two good questions. So the first answer is from a technology perspective. They were looking for a platform that is open, number one. So we work with all these different cameras. They were also looking for a partner for the future. And we have three new applications that are going to be rolled out in the next few months. And so based on that, none of our competitors were actually at the same level as Diagnose. So the investment, the strategic investment that I did and the architecture of what I built was the winner in terms of technology. The second part is that they wanted a partner that was flexible. Meaning, if they want to turn left, I got to turn left. So if they want to go after a new camera or a new service, I will do it. I told them one of the key things that they were looking for is these new ISO certification for cybersecurity. We do all our transactions on the net, right? So we're a SaaS-based model. Now, the cybersecurity protocols called 27001 is extremely complicated to deal with. It has to do with confidential information, what you do, how you treat it. So we committed to become a 27,000 approved this year, probably in the next six months. Again, the other competitors didn't want to do this because it's very, very complicated. And so that's another reason. Now, your last question is an important tool. Why did they pick a little company in Quebec of 14 people? I mean, there's the technology, but there's also the sense of partnership with them. I've been working on this for three years. So it's not something that's new. I mean, COVID did slow us down enormously. Even after COVID, it was very slow. And now, I think the markets are coming back to almost to be normal. And we were patient enough to work with them. And I went to Paris many times in Italy. I mean, that's where the head office are. I got to build relationships with these people. They're very, very nice people. And I think my background added a lot to it because I worked for multi-nationals all my life. I mean, diagnosed for me is, I left the big companies to start diagnosed, basically. So I know and I understand how to talk to them. And it's not just telling them what they want to hear. For example, they wanted me to take care of the US. I said, well, I can't. I mean, if I tell you I can do it today, and if I screw up, then I lose everything. So I said, I'd rather start with Canada. And by the way, it's still a $75 million market with one test. Once I have four tests, you're looking at like a quarter billion dollar market just here in Canada. I said, let me start with Canada. And in parallel, we'll take on some of the projects in the US. Not all of them because I cannot. So we're going to grow. It's for us, it's really a game changer, like we say in the business, right? We're going to grow. We're 14 people. We just hired number 15. And we probably have to hire no more than six to 10 people to actually handle the load for Canada in part of the other countries they want to do also. Well, you just answered my next question was, how are you going to deal with the growth demands that are obviously going to happen here? Yeah. But your expertise. We start with Canada and then in parallel, we'll do some other ones. But we need to be, I'm very conscious that I cannot do everything today. But I know one thing, we're going to grow. And what we do is sustainable. And I don't think there's any more risk. We're going to grow. And we're going to grow, even if it's a slow pace, it's always going to grow every month. So I'm pretty excited. I mean, I don't sleep at night because now it's like having a real, real big multinational business. Well, on that note, we'd like to congratulate you on your news. We'd also like to congratulate the institution that was sharp enough to initiate a research report on you so rapidly. Congratulations, Andre. And we hope you will do regular interviews with us and or have your team do it as you're trying to keep up with the pace and the demand of 2024. Happy holidays. Thank you very much, Tracy.